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Abstract
Among infants with prematurity and/or chronic lung disease for whom respiratory syncytial virus
immunoprophylaxis is recommended, we examined adherence in infants enrolled during
healthcare visits for acute respiratory illness in 3 US counties from 2001 to 2007.
Immunoprophylaxis among infants who met national criteria for prophylaxis increased from 33%
to 83% over the 6-year period; 17% (11/65) of infants who received immunoprophylaxis did not
meet eligibility criteria.
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Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections in
children,1 with chronic lung disease (CLD), prematurity and congenital heart disease (CHD)
conferring the highest risk for severe disease.2 Palivizumab, a monoclonal antibody to the
RSV F protein, reduces RSV hospitalizations among high-risk children when administered
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as immunoprophylaxis.3 We evaluated adherence to American Academy of Pediatrics
(AAP) recommendations for palivizumab use in infants with CLD and/or prematurity from 3
US counties.4–6
MATERIALS AND METHODS
The Centers for Disease Control and Prevention–funded New Vaccine Surveillance Network
(NVSN) supported prospective, population-based surveillance among children less than 5
years of age with healthcare encounters for acute respiratory illnesses and/or fever in 3
urban counties (Davidson County [Nashville], TN; Monroe County [Rochester], NY; and
Hamilton County [Cincinnati], OH).7,8 Both the NVSN network and this substudy, nested
within the NVSN, were approved by the Institutional Review Boards at each of the
participating institutions and the Centers for Disease Control and Prevention.
Study Population
After obtaining informed consent, research staff administered questionnaires to parents for
information on high-risk conditions (CLD/bronchopulmonary dysplasia, prematurity, CHD),
second-hand smoke exposure (SHS) and day-care attendance. During study years 2001 to
2007, the question “Has your child received palivizumab (Synagis) during fall/winter?” was
added to the questionnaire. Nasal and throat swabs were obtained and tested for RSV using
previously described reverse-transcription polymerase chain reaction methods.8
To evaluate adherence to palivizumab recommendations, only infants who met the following
criteria were included in this substudy: enrolled during the 2001 to 2007 RSV seasons, less
than 1 year of age at enrollment, successful linkage to birth certificate to determine
estimated gestational age (EGA)9 and parent reported whether the infant received
palivizumab (infants whose parents gave a response of unknown were excluded). In
addition, it was determined a priori that only infants with swabs testing negative for RSV
would be included in the adherence estimates because RSV-positive infants are
overrepresented in the study sample and would be expected to have lower rates of adherence
if immunoprophylaxis was protective.
Adherence to AAP Recommendations
Adherence to AAP recommendations released during study years 1998, 2003 and 2006 was
assessed.4–6 The start of the RSV season each year was defined to be November. Eligible
infants were categorized into 4 mutually exclusive groups, based on AAP recommendations:
(1) history of CLD (bronchopulmonary dysplasia) and age <12 months at start of RSV
season; (2) EGA of <29 weeks and age <12 months at start of RSV season; (3) EGA
between 29 and <32 weeks and age <6 months at start of RSV season; and (4) EGA of 32 to
<35 weeks, age <6 months at start of RSV season and parental report of both SHS and day-
care attendance. AAP recommendations regarding palivizumab eligibility for infants
between 32 and <35 weeks EGA included more than 1 risk factor and age <6 months at the
start of RSV season.4,6 SHS exposure and day-care attendance were the only 2 risk factors
we were able to determine for all infants. Infants with parental report of CHD were excluded
because data on the specific type of heart disease were not collected and thus we were not
able to determine eligibility.
Definition of Palivizumab Administration
Children whose parents reported that their infant received palivizumab were considered
recipients. We reviewed the medical records of the 7 eligible infants with complete medical
records available to validate parental report of immunoprophylaxis. In addition, for the
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infants whose parents reported that the child received palivizumab but did not meet the AAP
criteria, medical records were also reviewed to reassess eligibility.
Analysis
Infants included in the 4 eligibility groups and receiving palivizumab and those not included
in the 4 eligibility groups but still receiving palivizumab were determined. The Wilson
method was used to calculate 95% confidence intervals (CIs) assuming a binomial
distribution. Fisher exact test was used to compare the percentage of infants included in the
4 eligibility groups that received palivizumab. Chi-square test was used to evaluate the trend
in the proportions of eligible infants who received palivizumab.
RESULTS
Overall, 1557 infants were enrolled from the 3 study sites (946, 197 and 414 from Davidson,
Monroe and Hamilton counties, respectively; Fig. 1). There were 736, 396 and 425 infants
enrolled in hospitals, emergency departments and clinics, respectively. More infants from
Davidson County were included because Monroe County was unable to link to birth
certificate data in the early study years, and Hamilton County did not participate in the
NVSN until 2003. In addition, birth certificate linkage was higher in Davidson County
(96%) than the other sites (61% Monroe, 76% Hamilton).
In total, 57 of 1557 infants (3.7%) were determined to be in the AAP-defined eligibility
groups: 20 infants with parental report of CLD, 14 infants with EGA of <29 weeks and 23
infants with EGA between 29 and <32 weeks and aged <6 months at start of RSV season.
No infant with EGA between 32 and <35 weeks, age <6 months at start of RSV season and
both SHS and day-care exposure was identified. Among the 57 eligible infants (ranging
from 3 to 13 annually), 70% had public insurance, 58% were male and 58% were African
American.
Overall, 40 of 57 (70%; 95% CI: 56.6–81.6) infants in the eligibility groups received
palivizumab by parental report. Comprehensive medical records were available on 7 of these
57 infants, and palivizumab administration was confirmed in 6 (86%). Of the 20 infants with
CLD (ranging from 1 to 5 annually), 90% (95% CI: 69.9–97.2) received palivizumab,
compared with 59% (95% CI: 43.5–73.7) receiving palivizumab in the other eligibility
groups. Among infants included in the AAP-defined eligibility groups, there was a
significant increase in the proportion who received palivizumab, from 33% (2001–2002) to
83% (2006–2007), P = 0.008.
Overall, 1500 infants did not fall into any of the 4 eligibility groups. However, 29 of these
infants were reported to have received palivizumab. Comprehensive medical record review
in 26 of these 29 infants was completed. Eleven were classified into one of the eligibility
groups and should have received palivizumab. In addition, 15 infants did not meet eligibility
criteria and should not have received palivizumab, including 9 infants in the 32 to <35
weeks EGA group who did not meet national eligibility criteria because they had only a
single risk factor (7 infants) or were older than 6 months at the start of the RSV season (2
infants). Finally, parental report of palivizumab was likely inaccurate in 4 term or near-term
infants as medical records did not indicate immunoprophylaxis. Overall, 14 of the 26 records
reviewed contained the child’s medication administration history with 11 (79%) having
documentation of palivizumab administration, and 10 of 11 receiving it throughout the RSV
season. Thus, of the 26 infants who did not meet eligibility criteria and were reported by the
parents to receive palivizumab, medical record review indicated that 11 of these infants
received palivizumab without appropriate indications, accounting for 17% (11/65) of all
treated infants.
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In infants enrolled in the NVSN with acute respiratory illness or fever residing in 3 US
counties, adherence to palivizumab recommendations for infants with CLD and/or
prematurity increased from 33% in 2001 to 2002 to over 80% in 2005 to 2007. Differences
in study methodology, adherence definitions and study periods limit direct comparisons of
this population to earlier published reports; however, adherence was similar to the
approximately 70% adherence reported in Florida Medicaid recipients in 2004 to 2005.10
We also found that 17% of infants receiving palivizumab did not meet eligibility criteria, a
percentage lower than some earlier reports, but higher than percentages found in some
studies after intervention programs.10,11
Our study had limitations. First, infants were enrolled in different healthcare settings, and
although most hospitalizations in study counties were included, only selected outpatient
visits were captured. Second, 2 sites contributed only 4 years of data. Next, verification of
palivizumab administration in each infant, complete medical record review to document
type of CHD and documentation of medication use to classify infants with CLD were not
included. However, our limited review of medical records found that parental report of
palivizumab administration had a positive predictive value of 86% among infants who met
eligibility criteria. We included all infants in the <28 weeks EGA group who were less than
1 year of age at enrollment and did not limit inclusion to only their first RSV season, as per
the recommendations starting in December 2003.6 Other limitations included that some
infants in the 32 to <35 weeks EGA group may have been misclassified as ineligible because
we did not have complete information on all risk factors and the small number of cases each
year. Finally, we did not assess interventions that might have increased or modified
palivizumab adherence.10–12
In this real-world assessment of adherence to palivizumab, we found increasing adherence to
AAP recommendations during the 6-year period in our study population, but still 17% of
treated infants did not meet AAP eligibility criteria.
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The number of infants enrolled in the New Vaccine Surveillance Network (NVSN) in
Davidson, Rochester and Hamilton counties during 2001 to 2007, the reasons for and
number of exclusions and the final number of infants included in current substudy
population.
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